This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Advantage of Lutetium-177 versus Radioiodine Immunoconjugate in Targeted Radionuclide Therapy of B-cell Tumors
- 131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose-Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
- Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
- Accurate Dosimetry in 131I Radionuclide Therapy Using Patient-Specific, 3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation
- Impact of Nodal Regression on Radiation Dose for Lymphoma Patients After Radioimmunotherapy
- Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
- Potentiation of Radioimmunotherapy with Response-Selective Peptide Agonist of Human C5a
- Metabolite Production in Patients with Lymphoma After Radiometal-Labeled Antibody Administration